# MEDICAL PRE-AUTHORIZATION CRITERIA

## Genetic Testing, BRCA 1 & 2

### CPT/HCPCS CODES

81162, 81211, 81212, 81213, 81214, 81215, 81216, 81217

### CRITERIA FOR BRCA 1 AND 2 COMPREHENSIVE SEQUENCE ANALYSIS, FOUNDER MUTATIONS

MUST MEET ALL OF THE FOLLOWING:

1. The results of the genetic testing will directly impact surveillance or treatment of the member.
2. One of the following criteria is met:
   a. Three or more close relatives† (including the member) on the same side of the family have breast (either invasive or non-invasive) or ovarian cancer (includes epithelial ovarian/fallopian tube/primary peritoneal cancers), irrespective of the age at diagnosis.
   b. There are fewer than three close relatives on the same side of the family with breast or ovarian cancer, but any of the following are present:
      1) The member or a close relative was diagnosed with breast cancer at ≤ 45 years of age;
      2) A close relative has been identified with a detectable BRCA 1 or 2 mutation;
      3) The member or a close relative was diagnosed with breast cancer ≤ 50 years of age and one of the following:
         a) ≥ 1 close relative was diagnosed with breast cancer at any age;
         b) ≥ 1 close relative with pancreatic cancer;
         c) ≥ 1 close relative with prostate cancer (Gleason score ≥ 7);
         d) two primary breast cancers (including bilateral disease or two or more separate primary tumors in the same breast);
         e) there is an unknown or limited family history.²
      4) The member was diagnosed with breast cancer at any age and one of the following:
         a) ≥ 1 close relative was diagnosed with breast cancer ≤ 50 years of age;
         b) ≥ 2 close relatives with breast cancer at any age;
         c) ≥ 2 close blood relatives with pancreatic cancer and/or aggressive prostate cancer (Gleason score ≥ 7) at any age.
      5) The member or a close relative was diagnosed with triple negative breast cancer ≤ 60 years of age.³
      6) The member or a close relative was diagnosed with ovarian cancer, fallopian tube or primary peritoneal cancer at any age.
      7) The member or a close relative with breast cancer is male.
      8) The member or a close relative was diagnosed with breast cancer at any age and is at increased risk for specific mutation(s) due to ethnic background (for instance: Ashkenazi Jewish descent).⁴
   c. The member or a close relative was diagnosed with pancreatic cancer at any age with ≥ 1 close relative with ovarian cancer at any age or breast cancer ≤ 50 or two relatives with breast, pancreatic or prostate cancer (Gleason score ≥ 7) at any age.
   d. The member or a close relative was diagnosed with prostate cancer (Gleason score ≥7) at any age with ≥ 1 close relative with ovarian cancer at any age or breast cancer ≤ 50 or two close relatives with breast, pancreatic or prostate cancer (Gleason score ≥ 7) at any age.

To view ConnectiCare’s list of policies on various medical treatments and emerging technologies, go to www.connecticare.com/provider/MedicalPolicyCriteria.aspx

[^Back to Top]

Medical Pre-Authorization Criteria
Genetic Testing, BRCA 1 & 2 (BRAC Analysis)
Page 1 of 4
### CRITERIA FOR BRCA 1 AND 2 COMPREHENSIVE SEQUENCE ANALYSIS, FOUNDER MUTATIONS (continued)

e. A third-degree relative has breast and/or ovarian cancer (including fallopian tube or primary peritoneal cancer) and who has ≥ two close relatives with breast cancer (at least one with breast cancer ≤ 50) and/or ovarian cancer.

1. A close relative is defined as a 1st, 2nd or 3rd degree relative (a parent, full sibling, half sibling, child, grandparent, great-grandparent, grandchild, aunt, great aunt, uncle, great uncle, nephew, niece, or first cousin).

2. A limited family history is defined as fewer than two first- or second-degree female relatives or female relatives surviving beyond 45 years in either lineage (maternal and paternal).

3. Breast cancer that is negative for Estrogen receptor (ER), Progesterone receptor (PR) and HER2.

4. Authorization will initially be for the mutation(s) specific for the ethnic group in question (Multisite 3 BRACAnalysis® or equivalent testing for Founder Mutations). If the initial screening is negative, the member should be authorized for additional genetic testing (Comprehensive Sequence Analysis) only if he/she meets the remainder of the criteria.

### CRITERIA FOR BRCA 1 AND 2 DUPLICATION/DELETION ANALYSIS, UNCOMMON VARIANTS

**MUST MEET THE FOLLOWING:**

1. The member meets criteria for Comprehensive Sequence Analysis; the analysis has been completed and is negative.

### REFERENCES


